MDWD MediWound
- 17.420
- +0.130+0.75%
MediWound News
MediWound Ltd.'s (NASDAQ:MDWD) P/S Is Still On The Mark Following 25% Share Price Bounce
Despite an already strong run, MediWound Ltd. (NASDAQ:MDWD) shares have been powering on, with a gain of 25% in the last thirty days. Looking back a bit further, it's encouraging to see the stock i
MediWound to Present New Data From EscharEx Phase II Studies at Three Leading Wound Care Conferences
Oral presentations include additional comparative data between EscharEx and SANTYL, and new analyses show strong correlation between wound bed preparation and wound healingAnalyses validate the planne
Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)
Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
MediWound Ltd. (NASDAQ:MDWD) Yearly Results: Here's What Analysts Are Forecasting For This Year
As you might know, MediWound Ltd. (NASDAQ:MDWD) recently reported its full-year numbers. The results look positive overall; while revenues of US$19m were in line with analyst predictions, statu
MediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Medtronic (MDT) and Mediwound (MDWD)
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:MDWD) with a Buy and maintains $28 price target.
MediWound Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 70.73% HC Wainwright & Co. → $28 Reiterates Buy → Buy 01/16/2024 70.73% HC Wainwright & Co. $26
Mediwound Poised for Growth: A Strong Buy Recommendation Amidst Promising Prospects and Strategic Expansion
Earnings Call Summary | MediWound(MDWD.US) Q4 2023 Earnings Conference
The following is a summary of the MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript:Financial Performance:MediWound reported full year 2023 revenue of $19 million, driven largely by sales of Nexo
MediWound Boasts Robust 2023 Financials and Growth
MediWound Reports Mixed Q4 Results; Initiates FY24 Outlook
MediWound Q4 EPS $(0.19) Beats $(0.23) Estimate, Sales $5.34M Beat $5.32M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 83.9 percent increase over losses of $(1.18) per
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, Vs. Street Est of $5.3M
07:03 AM EDT, 03/21/2024 (MT Newswires) -- Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M
MediWound 4Q Loss/Shr 19c >MDWD
MediWound 4Q Loss/Shr 19c >MDWD
Press Release: MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update $19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid(R) commercially launched
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. • InflaRx (NASDAQ:IFRX) is projected to
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx to begin Phase III in the second half of 2024$42 mi
MediWound Q4 2023 Earnings Preview
Analysis
Price Target
No Data
